Clinigen, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$26.3M
Doctors Paid
132
Transactions
303
2024 Total
$251,921
Payment Breakdown by Category
Research$26.2M (99.7%)
Consulting$43,654 (0.2%)
Food & Beverage$12,417 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26.2M | 94 | 99.7% |
| Consulting Fee | $43,654 | 21 | 0.2% |
| Food and Beverage | $12,417 | 181 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,750 | 2 | 0.0% |
| Grant | $4,109 | 2 | 0.0% |
| Honoraria | $200.00 | 1 | 0.0% |
| Education | $13.72 | 2 | 0.0% |
Payments by Type
Research
$26.2M
94 transactions
General
$69,144
209 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase II Trial of Daily LD IL-2 | $3.8M | 0 | 4 |
| Phase 2 Study of Adoptive Transfer of Autologous TIL in Patients with Metastatic Uveal Melanoma | $2.3M | 0 | 4 |
| PHASE II TRIAL OF DAILY LD IL-2 | $1.5M | 0 | 2 |
| PHASE I TRIAL OF REGULATORY T-CELLS PLUS LD IL-2 FOR STEROID-REFRACTORY CGVHD | $1.4M | 0 | 2 |
| Lymphodepletion +ACT Without Dendritic Cell Immunization | $1.2M | 0 | 4 |
| LOW DOSE SUB CUTANEOUS IL-2 IN CROHNS DISEASE | $1.2M | 0 | 4 |
| CD40L-AUGMENTED (TIL) FOR ONCOGENE-DRIVEN ADVANCED NSCLC | $1.1M | 0 | 1 |
| 3 IITS TIL | $1.1M | 0 | 1 |
| TIL derived from NSCLC | $1.0M | 0 | 4 |
| MELANOMA AND RENAL CELL CARCINOMA | $1.0M | 0 | 1 |
| 5 TIL TRIALS WITH HD IL-2 IN MULTIPLE TUMORS | $966,367 | 0 | 2 |
| LYMPHODEPLETION +ACT WITHOUT DENDRITIC CELL IMMUNIZATION | $894,404 | 0 | 1 |
| Feasibility and Safety Investigation of ACT using TIL in multiple cancers | $788,410 | 0 | 2 |
| PHASE II TRIAL OF COMBINATION ANTI-PD-1 AND ALDESLEUKIN FOR METASTATIC | $771,038 | 0 | 1 |
| PHASE II TRIAL OF LD IL-2 ADDED TO EXTRA-CORPOREAL PHOTOPHERESIS FOR STEROID-REFRACTORY CGVHD | $648,083 | 0 | 2 |
| ADOPTIVE CELL THERAPY IN SELECTED CD39CD103 T CELLS IN MM AND SCHN | $582,904 | 0 | 1 |
| TILFOLLOWING IL-2 IN METASTATIC MELANOMA | $555,147 | 0 | 1 |
| HD IL-2 IN COMBINATION WITH PEMBRO MM AND RCC | $555,147 | 0 | 1 |
| Low Dose IL-2 for Ulcerative Colitis | $515,130 | 0 | 1 |
| LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE | $421,524 | 0 | 2 |
| Phase I Trial of Lymphodepletion followed by Adoptive Cell Transfer of Autologous TIL and HD IL-2 in Select Solid Tumors | $416,860 | 0 | 3 |
| NEOANTIGEN TCRT | $340,490 | 0 | 2 |
| T-cell receptor gene therapy targeting mutant KRAS in pancreatic cancer | $262,282 | 0 | 1 |
| PROLEUKIN 22MM IU VL CLIN TRIAL | $226,474 | 0 | 3 |
| Autologous T-regs + IL-2 in ALS | $210,778 | 0 | 2 |
| Phase I Clinical Trial Combining Nivo and ACT for mNSCLC | $177,954 | 0 | 1 |
| T CELL RECEPTOR GENE THERAPY TARGETINGKK-LC-1 CANCERS | $166,544 | 0 | 1 |
| PHASE IB TRIAL INTRAPERITONEAL IL-2 AND PD-1 INHIBITION IN GASTRIC CANCER | $166,544 | 0 | 1 |
| A BIOMARKER STUDY OF LOW-DOSE IL-2 + PEMBRO | $166,544 | 0 | 1 |
| SINGLE PT IND- TGFB RESIS TIL + IPI AND NIVO IN PT W PERITONEAL CA | $164,488 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Medical Oncology | $24,440 | 25 | $977.58 |
| Hematology & Oncology | $19,491 | 32 | $609.09 |
| Dermatology | $12,000 | 1 | $12,000 |
| Internal Medicine | $4,110 | 12 | $342.53 |
| Gynecology | $1,400 | 1 | $1,400 |
| Adult Health | $1,000 | 1 | $1,000 |
| Specialist | $805.71 | 7 | $115.10 |
| Urology | $726.71 | 36 | $20.19 |
| Clinical Genetics (M.D.) | $302.40 | 1 | $302.40 |
| Neurology | $302.40 | 1 | $302.40 |
| Surgical Oncology | $134.73 | 2 | $67.37 |
| Hematology | $111.60 | 3 | $37.20 |
| Student in an Organized Health Care Education/Training Program | $68.32 | 3 | $22.77 |
| Radiation Oncology | $64.35 | 3 | $21.45 |
| Surgery | $56.27 | 3 | $18.76 |
| Registered Nurse | $21.40 | 1 | $21.40 |
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Lewis Harpster, Md, MD | Urology | Harrisburg, PA | $12.48 | $0 |
| Rajen Butani, Md, MD | Urology | Linwood, NJ | $11.89 | $0 |
| Robert Barsky, D.o, D.O | Urology | Cherry Hill, NJ | $11.89 | $0 |
| Dr. John Migliano, M.d, M.D | Internal Medicine | Tucson, AZ | $11.68 | $0 |
| Vishwanath Gharpure, M.d, M.D | Hematology & Oncology | Plainsboro, NJ | $11.16 | $0 |
| Peter Pickens, M.d, M.D | Hematology & Oncology | Horsham, PA | $11.16 | $0 |
| Dr. Michael Seidman, Md, MD | Hematology & Oncology | Horsham, PA | $11.16 | $0 |
About Clinigen, Inc.
Clinigen, Inc. has made $26.3M in payments to 132 healthcare providers, recorded across 303 transactions in the CMS Open Payments database. In 2024, the company paid $251,921. The top product by payment volume is PROLEUKIN ($13.9M).
Payments were distributed across 16 medical specialties. The top specialty by payment amount is Medical Oncology ($24,440 to 25 doctors).
Payment categories include: Food & Beverage ($12,417), Consulting ($43,654), Research ($26.2M).
Clinigen, Inc. is associated with 2 products in the CMS Open Payments database.